The Unlikely Rally: Why Pfizer’s Stock Climbed Despite a Setback
Pfizer's stock rose 1.5% despite halting development of its weight loss drug, danuglipron, due to safety concerns. Investors remain optimistic about Pfizer's future, focusing on its development of PF-07976016, a…